{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:41:29Z","timestamp":1792456889266,"version":"4.5.0"},"reference-count":77,"publisher":"Korean Stroke Society","issue":"3","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["j-stroke.org"],"crossmark-restriction":true},"short-container-title":["J Stroke"],"published-print":{"date-parts":[[2026,9,30]]},"abstract":"<jats:p>Intravenous thrombolysis with alteplase is a primary reperfusion therapy for acute ischemic stroke, yet its clinical utility is constrained by a short half-life, continuous infusion requirements, and susceptibility to plasminogen activator inhibitor-1. Tenecteplase, a bioengineered variant of alteplase, was developed to address these limitations through a prolonged half-life, increased fibrin specificity, and enhanced resistance to plasminogen activator inhibitor-1. These structural modifications enable single-bolus administration and reduce systemic fibrinolytic disturbance. In this review, we examine how the targeted molecular modifications of tenecteplase shaped its stepwise translational development in acute ischemic stroke. We first detail the limitations of alteplase, which motivated the transition to alternative agents, the molecular rationale for tenecteplase, and its preclinical evidence. Furthermore, we synthesize the phase II dose-finding trials that established 0.25 mg\/kg as providing the optimal efficacy and safety balance, distinguishing it from the excess intracranial hemorrhage observed with the 0.4 mg\/kg dose. Finally, we review the pivotal phase III trials across diverse populations demonstrating that tenecteplase 0.25 mg\/kg is non-inferior to alteplase and represents a practical, evidence-based alternative, particularly where single-bolus administration may facilitate workflow or transfer for endovascular thrombectomy. Viewed through this molecular-to-clinical framework, the development of tenecteplase illustrates how targeted protein engineering can translate into pharmacological, operational, and clinical advantages in stroke reperfusion therapy.<\/jats:p>","DOI":"10.5853\/jos.2026.03412","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:49:47Z","timestamp":1791265787000},"page":"357-371","update-policy":"https:\/\/doi.org\/10.5853\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tenecteplase for Acute Ischemic Stroke: From Molecular Bioengineering to Phase III Pivotal Trials"],"prefix":"10.5853","volume":"28","author":[{"given":"Jae Wook","family":"Jung","sequence":"first","affiliation":[{"name":"Department of Neurology, Yonsei University College of Medicine, Seoul, Korea"},{"name":"Department of Radiology, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7225-6166","authenticated-orcid":true,"given":"Jin Soo","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ajou University School of Medicine, Ajou University Medical Center, Suwon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3882","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/2396987321989865","type":"journal-article"},{"key":"ref2","first-page":"e316","type":"journal-article","volume-title":"2026 Guideline for the early management of patients with acute ischemic stroke: a guideline from the American Heart Association\/American Stroke Association","author":"Prabhakaran","year":"2026"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.23.5.632","type":"journal-article"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.23.5.641","type":"journal-article"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199512143332401","type":"journal-article"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199906103402302","type":"journal-article"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.128618","type":"journal-article"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5853\/jos.2022.02880","type":"journal-article"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.120.031591","type":"journal-article"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.123.031692","type":"journal-article"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/358640","type":"journal-article"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1649571","type":"journal-article"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1649572","type":"journal-article"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.3670","type":"journal-article"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2003.09.009","type":"journal-article"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01391-3","type":"journal-article"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-2918(01)80086-2","type":"journal-article"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-4949.2012.00924.x","type":"journal-article"},{"key":"ref19","first-page":"e46","type":"journal-article","volume-title":"2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","author":"Powers","year":"2018"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.122.038950","type":"journal-article"},{"key":"ref21","first-page":"1573","type":"journal-article","volume-title":"Tenecteplase versus alteplase before thrombectomy for ischemic stroke","author":"Campbell","year":"2018"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.5853\/jos.2018.01998","type":"journal-article"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.5853\/jos.2013.15.2.90","type":"journal-article"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2019.06.023","type":"journal-article"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-290338","type":"journal-article"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-011-0049-x","type":"journal-article"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200212000-00009","type":"journal-article"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.92.10.3032","type":"journal-article"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.32.3.748","type":"journal-article"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/0271678x241237427","type":"journal-article"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/00912700022009125","type":"journal-article"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.95.2.351","type":"journal-article"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241150-00001","type":"journal-article"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.115.011290","type":"journal-article"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.98.25.2805","type":"journal-article"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-8703(99)70400-x","type":"journal-article"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(99)07403-6","type":"journal-article"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-8703(03)00117-0","type":"journal-article"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.0000154872.73240.e9","type":"journal-article"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.109.572040","type":"journal-article"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1109842","type":"journal-article"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2021-000978","type":"journal-article"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(15)70017-7","type":"journal-article"},{"key":"ref44","first-page":"769","type":"journal-article","volume-title":"Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion","author":"Coutts","year":"2015"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00171-5","type":"journal-article"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2023-002820","type":"journal-article"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1177\/1747493016641112","type":"journal-article"},{"key":"ref48","first-page":"e1292","type":"journal-article","volume-title":"Safety and efficacy of tenecteplase in older patients with large vessel occlusion: a pooled analysis of the EXTEND-IA TNK trials","author":"Yogendrakumar","year":"2022"},{"key":"ref49","first-page":"1257","type":"journal-article","volume-title":"Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK part 2 randomized clinical trial","author":"Campbell","year":"2020"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(17)30253-3","type":"journal-article"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00124-7","type":"journal-article"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.123.030320","type":"journal-article"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.5853\/jos.2024.03923","type":"journal-article"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.5853\/jos.2024.04119","type":"journal-article"},{"key":"ref55","first-page":"161","type":"journal-article","volume-title":"Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial","author":"Menon","year":"2022"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2023-002828","type":"journal-article"},{"key":"ref57","first-page":"645","type":"journal-article","volume-title":"Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial","author":"Wang","year":"2023"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(24)00377-6","type":"journal-article"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.14721","type":"journal-article"},{"key":"ref60","first-page":"775","type":"journal-article","volume-title":"Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4\u00b75 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial","author":"Parsons","year":"2024"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.5853\/jos.2024.01284","type":"journal-article"},{"key":"ref62","first-page":"e209903","type":"journal-article","volume-title":"Tenecteplase vs alteplase in acute ischemic stroke within 4.5 hours: a systematic review and meta-analysis of randomized trials","author":"Palaiodimou","year":"2024"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1177\/23969873221150022","type":"journal-article"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2022.344","type":"journal-article"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2025.0210","type":"journal-article"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.5853\/jos.2024.03062","type":"journal-article"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.5853\/jos.2023.03713","type":"journal-article"},{"key":"ref68","first-page":"579","type":"journal-article","volume-title":"Intra-arterial tenecteplase following endovascular reperfusion for large vessel occlusion acute ischemic stroke: the POST-TNK randomized clinical trial","author":"Huang","year":"2025"},{"key":"ref69","first-page":"582","type":"journal-article","volume-title":"Intra-arterial tenecteplase for acute stroke after successful endovascular therapy: the ANGEL-TNK randomized clinical trial","author":"Miao","year":"2025"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080489","type":"journal-article"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.5853\/jos.2024.05715","type":"journal-article"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.5853\/jos.2023.00668","type":"journal-article"},{"key":"ref73","first-page":"344","type":"journal-article","volume-title":"Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the CHABLIS-T II randomized clinical trial","author":"Cheng","year":"2025"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2402980","type":"journal-article"},{"key":"ref75","first-page":"1137","type":"journal-article","volume-title":"Tenecteplase for acute non-large vessel occlusion 4.5 to 24 hours after ischemic stroke: the OPTION randomized clinical trial","author":"Ma","year":"2026"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2310392","type":"journal-article"},{"key":"ref77","first-page":"1849","type":"journal-article","volume-title":"Intravenous tenecteplase prior to endovascular treatment for ischemic stroke at 4.5 to 24 hours: the TNK-PLUS randomized clinical trial","author":"Xiong","year":"2026"}],"container-title":["Journal of Stroke"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/j-stroke.org\/upload\/pdf\/jos-2026-03412.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/j-stroke.org\/journal\/view.php?doi=10.5853\/jos.2026.03412","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/j-stroke.org\/upload\/pdf\/jos-2026-03412.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:25:39Z","timestamp":1792455939000},"score":1,"resource":{"primary":{"URL":"http:\/\/j-stroke.org\/journal\/view.php?doi=10.5853\/jos.2026.03412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.5853\/jos.2026.03412","relation":{},"ISSN":["2287-6391","2287-6405"],"issn-type":[{"value":"2287-6391","type":"print"},{"value":"2287-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"2026-05-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-30","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-30","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}